Payment overview · 2025
General Payments
$90,797.82
164 reported records · 7 companies
Healthcare provider profile · identity verified
Fares Khater, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WHITESBURG, KY · NPI 1992732101
Verified facts
What the public records show
CMS Open Payments records show Fares Khater, MD received $90,797.82 in general payments during 2025 across 164 reported records.
Gilead Sciences, Inc. accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Biktarvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $36,733.96 | 40.5% | 53 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31,285.61 | 34.5% | 66 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $13,072.81 | 14.4% | 24 | 2025 |
| Melinta Therapeutics, LLC | Unresolved — no canonical attribution shown | $8,645.68 | 9.5% | 17 | 2025 |
| OraSure Technologies Inc. | Unresolved — no canonical attribution shown | $1,000.00 | 1.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.26 | 0.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.50 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $66,792.75 | 26 |
| Consulting Fee | $10,475.00 | 5 |
| Travel and Lodging | $10,226.05 | 55 |
| Food and Beverage | $3,304.02 | 78 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $34,669.04 | 43 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $31,274.34 | 65 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $8,725.10 | 18 | 2025 |
Source payment records
|
|||||
| Rezzayo Normalized: rezzayo |
Drug | Melinta Therapeutics, LLC | $4,953.91 | 9 | 2025 |
Source payment records
|
|||||
| XACDURO Normalized: xacduro |
Drug | La Jolla Pharmaceutical Company | $4,177.71 | 5 | 2025 |
Source payment records
|
|||||
| Kimyrsa Normalized: kimyrsa |
Drug | Melinta Therapeutics, LLC | $3,626.36 | 7 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $1,760.59 | 5 | 2025 |
Source payment records
|
|||||
| InteliSwab Normalized: inteliswab |
Device | OraSure Technologies Inc. | $1,000.00 | 1 | 2025 |
Source payment records
|
|||||
| GIAPREZA Normalized: giapreza |
Drug | La Jolla Pharmaceutical Company | $170.00 | 1 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $37.26 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.50 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $11.27 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $11.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 241 | 180 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 221 | 221 |
| Lisinopril | Lisinopril | 120 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 25 |
| Atorvastatin Calcium | Atorvastatin Calcium | 99 | 23 |
| Famotidine | Famotidine | 97 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 94 | 19 |
| Omeprazole | Omeprazole | 92 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 66 |
| Metformin Hcl | Metformin Hcl | 82 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 81 | 15 |
| Amlodipine Besylate | Amlodipine Besylate | 72 | 17 |
| Furosemide | Furosemide | 69 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 15 |
| Farxiga | Dapagliflozin Propanediol | 58 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | suppressed |
| Gabapentin | Gabapentin | 48 | suppressed |
| Simvastatin | Simvastatin | 48 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 40 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 46 | 31 |
| Valacyclovir | Valacyclovir Hcl | 46 | 17 |
| Allopurinol | Allopurinol | 44 | suppressed |
| Potassium Chloride | Potassium Chloride | 44 | 15 |
| Losartan Potassium | Losartan Potassium | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 21 |
| Hydrocortisone | Hydrocortisone | 32 | suppressed |
| Prednisone | Prednisone | 32 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | suppressed |
| Carvedilol | Carvedilol | 30 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 23 |
| Ventolin Hfa | Albuterol Sulfate | 28 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Emtricitabine-Tenofovir Disop | Emtricitabine/Tenofovir (Tdf) | 24 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 23 | 23 |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 18 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Entecavir | Entecavir | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 11 |
| Jardiance | Empagliflozin | 17 | suppressed |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Darunavir | Darunavir | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 11 |
| Ozempic | Semaglutide | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 12 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 12 | 11 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Methotrexate | Methotrexate Sodium | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Sofosbuvir-Velpatasvir | Sofosbuvir/Velpatasvir | 11 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 11 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $90,797.82 · 164 records | Gilead Sciences, Inc. | Biktarvy, Cologuard Collection Kit, Epclusa, GIAPREZA, InteliSwab, Kimyrsa, MAVYRET, QULIPTA, Rezzayo, UBRELVY, XACDURO, ZERBAXA, ZEVTERA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error